IBRX Similar Chart Price Prediction
The price of IBRX is predicted to go up 2.34%, based on the high correlation periods with EVN. The similarity of these two price pattern on the periods is 95.68%.
IBRX
EVN
Up: 2.34%Similarity: 95.68%
IBRX Revenue Forecast
IBRX EPS Forecast
IBRX FAQs
What is IBRX revenue forecast for next quarter？
IBRX Analyst's Forecast
Justin Zelin
BTIG
Strong Buy
2025-01-10
Price Target
$6
Upside
+147.93%
BTIG analyst Justin Zelin initiated coverage of ImmunityBio with a Buy rating and $6 price target. Lead product Anktiva is approved in BCG-unresponsive non-muscle invasive bladder cancer based on "compelling" complete response rates and durability, says the analyst, who sees the company's partnership with Serum Institute of India for development of recombinant BCG as "a prudent approach to address the BCG shortage long-term."
Jason Kolbert
EF Hutton
Strong Buy
2024-10-23
Price Target
$30
Upside
+767.05%
